Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLYP2N)

• Drug Name: AMG 757 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Neuroendocrine cancer	2B72.1	Phase 1	[1]
Small-cell lung cancer	2C25.Y	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMLYP2N

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[5]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[6]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[7]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[8]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[9]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[10]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[11]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[12]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[13]

Drug(s) Targeting Delta-like protein 3 (DLL3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rova-T	DMNGCAD	Small-cell lung cancer	2C25.Y	Phase 3	[14]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[13]
HPN328	DM1ZHML	Small-cell lung cancer	2C25.Y	Phase 1/2	[15]
AMG 119	DMKF1O2	Small-cell lung cancer	2C25.Y	Phase 1	[3]
RG6524	DMT22UV	Aggressive cancer	2A00-2F9Z	Phase 1	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Delta-like protein 3 (DLL3)	TT1C9K6	DLL3_HUMAN	Inhibitor	[3]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[3]

References

• [1] ClinicalTrials.gov (NCT04702737) A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of Amgen.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [6] Clinical pipeline report, company report or official report of Genmab.
• [7] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [8] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [9] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [10] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [11] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [12] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [13] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Clinical pipeline report, company report or official report of Harpoon Therapeutics.
• [16] Clinical pipeline report, company report or official report of Roche